News | Annuloplasty Rings | September 10, 2015

Carillon Mitral Contour System Deemed Cost-Effective Treatment for Functional Mitral Regurgitation

German study finds mitral annuloplasty treatment offers more benefit at lower cost compared to optimal medical treatment

Carillon mitral contour system, cost-effective, optimal medical treatment, OMT, TITAN, functional mitral regurgitation, FMR

Carillon mitral contour system image courtesy of Cardiac Dimensions Inc.

September 10, 2015 — The Carillon mitral contour system is projected to be a cost-effective treatment option when compared to a typical regimen of optimal medical treatment (OMT), the present standard of care for functional mitral regurgitation (FMR). This finding has been established in a new study published in BMC Cardiovascular Disorders.

Researchers analyzed data derived from the landmark TITAN clinical trial, which demonstrated significant clinical merits of the Carillon technology, and developed a comprehensive cost-effectiveness model that projects the costs of the technology and compares them to the benefits. The output shows the Carillon therapy to be cost-effective in comparison to OMT with an incremental cost-effectiveness ratio (ICER) of €15,533 per quality-adjusted life year (QALY).

ICER is considered to be a gold standard in terms of determining whether a new therapy is cost-effective, with amounts below €35,000/QALY typically considered to be cost effective. The analysis was conducted from the perspective of the German health insurance system.

“In multiple clinical trials, Carillon has demonstrated significant reductions in FMR and improvement in heart failure symptoms. This analysis takes the next step in projecting that these benefits result in the cost effectiveness of the therapy,” said Michael Haude, M.D. Ph.D., chief of cardiology at Lukaskrankenhaus in Neuss, Germany, and co-author of the study. “This positive assessment has substantial implications in terms of the utility and accessibility of the therapy.”

The Carillon mitral contour system is a percutaneous mitral annuloplasty treatment option that can be deployed rapidly and safely, utilizing standard interventional techniques. The implantable device consists of a distal anchor and a proximal anchor connected by a shaping ribbon and utilizes the heart’s venous anatomy to reshape the mitral annulus. This approach allows for reduction of the dilated annulus, addressing a root cause of FMR. The system has demonstrated compelling efficacy, significantly improving patients’ symptoms, mitral regurgitation and quality of life. In addition, all adjunctive treatment options remain available after using Carillon, making it an ideal first-line therapy for FMR.

For more information: www.cardiacdimensions.com

Related Content

SAVR, surgical aortic valve replacement, elderly patients, aortic stenosis, Society of Thoracic Surgeons, clinical study
News | Structural Heart | January 25, 2017
Elderly patients with aortic stenosis (AS) and medium surgical risk experienced better than expected results after...
Videos | Structural Heart | November 09, 2016
Brijeshwar Maini, M.D., and Brian Bethea, M.D., from Tenet Florida’s structural heart program, explain the importance
aortic dissection, family history, same age, clinical study, John A. Elefteriades, Annals of Thoracic Surgery
News | Structural Heart | August 25, 2016
People with a family member who had an aortic dissection — a spontaneous tear in one of the body’s main arteries —...
Videos | Structural Heart | June 30, 2016
Interview with Stephen Little, M.D., medical director of the Valve Clinic at the Houston Methodist DeBakey Heart and
AATS 2016, tricuspid regurgitation, post mitral valve repair, Tirone E. David, atrial fibrillation
News | Structural Heart | May 16, 2016
At the 96th American Association for Thoracic Surgery (AATS) Annual Meeting, investigators presented the results of a...
CABG, mitral valve repair, ischemic mitral regurgitation, IMR, study, ACC 2016
News | Structural Heart | April 11, 2016
Just-released two-year follow-up data comparing coronary-artery bypass grafting (CABG) with combined CABG and mitral-...
V-Wave Interarterial Shunt, first human results, The Lancet, heart failure, HF
News | Structural Heart | March 28, 2016
V-Wave Ltd, maker of an investigational interatrial shunt device for patients with advanced heart failure (HF),...
News | Structural Heart | March 02, 2016
Edwards Lifesciences Corp. announced U.S. Food and Drug Administration (FDA) approval to expand use of the Edwards...
AtriCure, AtriClip, ATLAS study, first patient enrolled, POAF, post-operative atrial fibrillation
News | Structural Heart | February 18, 2016
AtriCure Inc. announced that the first patient was enrolled and treated at PinnacleHealth Hospitals in Harrisburg, Pa...
HeartWare, terminated acquisition, Valtech Cardio
News | Structural Heart | February 10, 2016
February 10, 2016 — HeartWare International Inc. and Valtech Cardio Ltd.
Overlay Init